Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2023-08-29 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses operational highlights, R&D progress, sales performance, and business segment updates for the first half of 2023. The length of the document (7173 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive interim report rather than a brief announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-29 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' special statement and opinion regarding the company's external guarantees and related party fund occupation for the first half of 2023. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and provides detailed findings on guarantees and fund usage. The document is a standalone audit-related opinion focusing on compliance and financial guarantees, not a full annual or interim report. It does not contain comprehensive financial statements or management discussion but is a specialized audit opinion. Therefore, it fits the category of Audit Report / Information (AR). The document length is short but contains substantive audit content, not merely an announcement or certification, so it is not RNS or RPA. H1 2023
2023-08-29 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the first half of 2023 by 亿帆医药股份有限公司. It includes financial figures but is not a comprehensive financial report like an annual or interim report. It appears to be a specific disclosure related to related party transactions and fund usage rather than a full financial statement or management discussion. The document length is 2638 characters, which is relatively short and focused on a specific topic. It does not contain a full set of financial statements or management analysis, nor is it an announcement or certification. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory disclosure of related party transactions and fund usage that does not fit into other specific categories like Annual Report, Interim Report, or Audit Report.
2023-08-29 Chinese
半年报监事会决议公告
Board/Management Information Classification · 90% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 亿帆医药股份有限公司 regarding the approval of the company's 2023 semi-annual report and related financial matters. It includes voting results and confirms the legality and accuracy of the report preparation process. The document is short (917 characters) and primarily announces the approval of the semi-annual report rather than containing the full report itself. Therefore, it is not the Interim/Quarterly Report (IR) itself but an announcement related to governance and supervisory board decisions. It fits best under Board/Management Information (MANG) as it relates to supervisory board meeting resolutions and approvals of financial reports and related disclosures.
2023-08-29 Chinese
关于公司控股股东、实际控制人、董事长兼总裁提议公司回购股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from the company regarding a proposal by the controlling shareholder and chairman to repurchase company shares. It details the reasons, proposed methods, price limits, funding sources, and other specifics of the share buyback plan. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The document is clearly an announcement about a capital action (share repurchase). Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and focused solely on the share repurchase proposal, confirming it is not a full report or regulatory filing.
2023-08-20 Chinese
关于对全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 亿帆医药股份有限公司 regarding the progress of guarantees provided to its wholly-owned subsidiary 杭州鑫富科技有限公司. It details the guarantee agreements, financial data of the subsidiary, board approvals, and cumulative guarantee amounts. The document is an announcement about financing guarantees and related approvals, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit into categories like Board/Management changes, Earnings Release, or Legal Proceedings. The content focuses on capital/financing updates related to guarantees and credit facilities. The document length is 3519 characters, which is relatively short but contains substantive information about financing guarantees rather than just a notice of report publication. Therefore, the best fitting category is Capital/Financing Update (CAP).
2023-08-02 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.